EDIT · Editas Medicine, Inc.

🧪 Trial & FDA Catalysts

• Sep 2025 · Phase 1/2 · Active Trial · EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Tra
  Registry primary completion date, not a results date
• Aug 2025 · Phase 1/2 · Active Trial · A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle
  Registry primary completion date, not a results date
• May 2022 · N/A · Results Expected · Natural History Study of CEP290-Related Retinal Degeneration
  Registry primary completion date, not a results date

📊 Drug Pipeline

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

EDIT holds $393.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $26.3M/quarter from operations, an estimated runway of 44.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

• Cash runway 45 months
• Company says cash lasts into the second half of 2028 -10We expect that our existing cash and cash equivalents on June 30, 2026 will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2028 . 10-Q, Aug 2026
• Share count +71% in a year +20

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EDIT files for a raise →